City Therapeutics (CTY) Stock Price, News & Analysis

Company Overview

City Therapeutics is a biotechnology company developing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-related proteins. Its research focuses on designing RNAi therapies for potential use across a range of diseases.

Launched in 2024, the company is developing technology intended to advance the design and delivery of RNAi medicines. Its work is research and development focused; the company’s activities center on building a therapeutic pipeline rather than marketing established products.

Key Stats

• Today's Range: $16.93 to $20.33
• 50-Day Range: N/A
• 52-Week Range: $15.81 to $23.88
• Volume: 482,372 shs
• Average Volume: 338,021 shs
• Market Capitalization: $936.13 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $37.33
• Consensus Rating: Moderate Buy

City Therapeutics Stock Analysis - MarketRank™

City Therapeutics scored higher than 85% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

City Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

City Therapeutics has a consensus price target of $37.33, representing about 106.3% upside from its current price of $18.10.

Amount of Analyst Coverage

City Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.7 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for City Therapeutics are expected to grow in the coming year, from ($6.35) to ($2.58) per share.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.59% of the float of City Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

City Therapeutics has a short interest ratio ("days to cover") of 2.27, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in City Therapeutics has recently increased by 100.00%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

City Therapeutics does not currently pay a dividend.

Dividend Growth

City Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.51

News Sentiment

City Therapeutics has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for City Therapeutics this week, compared to 4 articles on an average week.

Search Interest

3 people have searched for CTY on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added City Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.6 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

2 insiders have purchased shares of City Therapeutics in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $6,120,000.00 in company stock, which represents 0.6538% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, City Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $6,120,000.00 in company stock and sold $0.00 in company stock.

Percentage Held by Institutions

City Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Today: 11/15/2026
• Jefferies Global Healthcare Conference: 11/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:CTY
• CIK: 2143850
• Web: www.citytx.com
• Phone: (857) 357-2024
• Fax: N/A
• Employees: 75
• Year Founded: N/A

Price Target and Rating

• Average Price Target for City Therapeutics: $37.33
• High Price Target: $46.00
• Low Price Target: $32.00
• Potential Upside/Downside: +106.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 51,720,000
• Free Float: N/A
• Market Cap: $936.13 million
• Optionable: N/A
• Beta: N/A